Children acquire neuropsychologic dysfunctions after chemotherapy for hematologic malignancy. In this study, putative changes in levels of CSF-tau (a marker of neural dysintegrity) in leukemic children prior to and during chemotherapy were studied. Cerebrospinal fluid (CSF) samples were obtained before and during treatment from patients with B cell non-Hodgkin's lymphoma (NHL, n = 10), non-B cell acute lymphoblastic leukemia/NHL (non-B-ALL, n = 48), acute myeloid leukemia (AML, n = 9), other malignant diseases (n = 9), and six control children. A sandwich-type ELISA (INNOTEST hTAU-Ag) was used for measuring CSF-tau. Sixteen out of 50 patients with hematological malignancies, including the patients with proven leukemic CNS invasion, already showed high CSF-tau levels at baseline (Ͼ300 pg/ml). The pre-induction treatment for non-B-ALL, consisting of only corticosteroids and methotrexate (MTX), resulted in a significant increase of tau at day 8 (on average to 535 pg/ml). Larger increases as compared to baseline levels of CSF-tau were observed in patients treated for B-NHL with systemic vincristine, corticosteroids and cyclophosphamide, and intrathecal MTX (mean 776 pg/ml at day 8). In two AML patients with CNS invasion, CSF-tau increased during chemotherapy up to 1500 and 948 pg/ml, respectively. In one non-B-ALL patient with MTX-induced clinical neurotoxicity, CSF-tau was above the detection limit of 2000 pg/ml. Almost one-third of the patients with hematological malignancies had elevated CSF-tau levels at diagnosis. Transient high levels of CSF-tau, reaching levels observed in other neurodegenerative disorders, were observed during induction chemotherapy for non-B-ALL, B-NHL and CNS + AML. The clinical implications of both observations will be the subject of further study. Leukemia
Introduction
The survival of children with malignancies has improved markedly over the past few decades. In particular, important progress was made during the 1970s and early 1980s in the treatment of childhood acute lymphoblastic leukemia (ALL), the most common pediatric malignancy, 1 with reported eventfree survival rates of around 70%. 2 Since then, treatment results have been somewhat further improved to almost 75%. 3 These positive results have also focused increased attention on post-therapeutic effects of antileukemic drugs. Of particular concern are potential central nervous system (CNS) sequelae. The long-term complications of the treatment (or prophylaxis) of childhood leukemias and brain tumors include behavioral changes, poor school performance, memory loss, intellectual decline, growth retardation, and hormonal disturbances. Unfortunately, in clinical practice, assessment of neurotoxicity can only be gauged several months or years after treatment. Therefore, the need for a marker reflecting neural (dys)integrity is relevant in order to develop a diagnostic tool for 'on-line' monitoring of CNS-invasion or neurotoxicity before and/or during treatment of leukemia. Since the cerebrospinal fluid (CSF) is in direct contact with the extracellular space of the brain, alterations in brain metabolic activity may probably be reflected by changes in the levels of CSF biochemical markers. The microtubuli-associated protein tau is abundantly present in neurons, where it promotes microtubule assembly and stability in the axonal compartment of neurons. 4 CSF-tau as a marker for neurodegeneration has already been well studied in patients with disorders such as Alzheimer's disease, stroke, and Creutzfeldt-Jakob disease. [5] [6] [7] We therefore carried out a pilot study to determine whether CSF-tau could be useful to monitor chemotherapy-related neurotoxicity in children being treated for hematological malignancies.
Patients and methods

Patients
Between August 1996 and July 1999, 512 samples of CSF were taken from 82 children being treated for cancer at the Pediatric Hemato-oncology Unit of the Catholic University of Leuven, Belgium. CSF samples were only taken in the course of scheduled lumbar punctions (LPs) for staging or treatment of malignancy.
Three groups of patients with hematological malignancies were studied (Table 1) . The largest group consisted of 48 patients with non-B-cell ALL (non-B-ALL), treated according to the EORTC protocol 58881. One patient had overt CNS involvement (CNS + ), defined according to the study protocol with malignant cells in the CSF. Five patients were considered as very high risk (VHR) patients according to the criteria defined in the protocol (two patients with t(9;22) and three patients with corticoid-resistance). As the first part of the induction treatment was similar in the other patients, they were included in the analyses for induction chemotherapy. Twenty-eight of the patients with non-B-ALL could be followed longitudinally during their treatment period. A second group of patients included 10 B cell non-Hodgkin's lym- Table 1 Characteristics of the patients enrolled in the present study All patients were treated with the same protocol, except one patient who had B cell leukemia. Six of these patients were studied longitudinally. A third patient group consisted of nine children with acute myeloid leukemia-myelodysplasia (AML-MDS), of which two patients had CNS involvement and two patients had Down's syndrome. Two patients had MDS: one developed AML and was treated with chemotherapy but died; the other patient is still untreated. The nine patients were treated according to the EORTC 58921 protocol and seven patients were followed longitudinally. The other patients consisted of a heterogenous group of children (n = 9) in whom a lumbar puncture was performed for clinical reasons. This group included three children with medulloblastoma (staging), two children with rhabdomyosarcoma (staging), one child with Langerhans cell histiocytosis (LCH, staging), ganglioglioma (staging), germinoma (staging), and retinoblastoma with CNS metastasis (staging and followup). Control samples were obtained from four children from whom CSF was taken as part of the routine control for possible viral or bacterial infections, but with negative results; from one patient with a localized retinoblastoma (staging), and from one patient screened for familial hemophagocytic lymphohistiocytosis (HLH). The nearest relatives of the patients gave oral informed consent for participation in the study.
Liquor sampling
Lumbar punctures were performed just prior to the intrathecal administration of therapeutics. Five ml of CSF was collected in different polypropylene vials. One sample was centrifuged immediately at 1500 r.p.m. for 2 min to eliminate cells and other insoluble material. The supernatant was stored at −70°C for subsequent analysis. The number of freeze/thaw cycles was restricted to a minimum.
Measurement of biochemical markers in the CSF
All biochemical analyses for the detection of CSF-Tau were made without knowledge of the clinical diagnosis. Potentially confounding factors, such as the number of freeze/thaw cycles, the material of the vials in which the CSF was sampled, and volume of sample per assay were standardized for the whole study protocol. All samples were tested undiluted.
Tau was measured by a sandwich-type assay (INNOTEST hTAU-Ag, Innogenetics, Gent, Belgium), using monoclonal antibody AT120 as coating antibody and a combination of two monoclonal antibodies, HT7 and BT2 as detector antibody, as described in detail previously. 8 The assay format allows the detection of non-phosphorylated and phosphorylated tau. For the ELISA, recombinant tau is used as standard. Tau standard levels range between 75 and 2000 pg/ml. The detection limit is ±59 pg/ml and is calculated as the mean of 12 determinations of the sample diluent +4 s.d. The recovery of tau spiked in seven different CSF samples is 92.2% ± 4.0 (s.d.). The intra-assay variation is measured by three parallel determinations of standards (1200 and 600 pg/ml) and five CSF samples. The coefficient of variation ranges from 1.2 to 5.9%. The inter-assay variation is determined on three consecutive runs of two standards and five CSF samples. Each run is a mean of six determinations. The coefficient of variation ranges from 1.7 to 6.0%.
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The increases of CSF-tau described here were excluded as being general increases of proteins in the liquor.
Statistical analysis
Non-parametric statistics were used for statistical analysis. The Kruskal-Wallis test was used to investigate group differences. A paired Friedman test was not applicable due to missing data at different time points (when the puncture procedure was difficult and no CSF was left for scientific investigations). In addition, Dunn's multiple comparison test was used to explore differences between the different groups. The Wilcoxon paired test was used to check in an explorative study for differences between the first diagnostic CSF-tau value and subsequent values (not corrected for multiple testing). The Mann-Whitney test was used to compare CSF-tau values between two groups. Analyses were done with Prism software v2.01 (Graphpad Software, San Diego, CA, USA).
Results
Tau levels before treatment
We first examinded the possible influence of age on CSF-tau levels obtained at first presentation, as we were not able to analyze CSF samples from a large group of healthy control children in order to determine the normal upper limit of CSFtau in childhood. All samples available before any treatment were correlated with age. As shown in Figure 1 , there was no correlation between CSF-Tau values and the age of the children (P Ͼ 0.05). It is known from previous studies that it is only in the first 3 months of life that the levels of CSF proteins are significantly different from those CSF values during the entire life-span. 9 It is also known for other nervous-specific proteins, which are quantifiable in CSF, that there is a slow increase of CNS-specific proteins in CSF with age regardless of whether the proteins are of neuronal or glial origin or whether the proteins are derived from oligodendrocytes.
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Thus, based on these assumptions, we infer that the normal upper limit for CSF-tau (300 pg/ml), obtained from data derived from adults, 5 is applicable as the normal upper limit
Figure 1
Relation of CSF-tau levels before treatment to patient age. All CSF samples available, before any treatment was started, were plotted against the ages of the patients. Age had no influence on the CSF-tau levels. Tau was detected with ELISA as described.
Leukemia for the children in our study. CSF-tau levels were not influenced by sex (P Ͼ 0.05). Tau levels at diagnosis were then analyzed for subgroups of patients ( Figure 2 ). There was no obvious difference for the CSF-tau levels in patients with and without Down's syndrome (P Ͼ 0.05). The CSF-tau levels in a few healthy children which could be analyzed (aged 1, 4, 5, 6, 11 and 19 years) were clearly below the proposed upper limit (mean 106.2 pg/ml, 95%Cl = 34.3-178.0). The two patients with overt CNS invasion (CNS + ) had high levels of CSF-tau (Ͼ300 pg/ml) at diagnosis. However, the two children with MDS, 8/28 children with non-B-ALL, 1/4 non-B-ALL patients with very high risk criteria, 1/5 patients with AML, and 2/8 patients with B cell NHL had levels of tau above 300 pg/ml, although using classical diagnostic procedures (according to the protocol: malignant cells in liquor, CT scan, and fundoscopy), CNS invasion was not detected. For 33 patients with non-B-ALL, CSF-tau levels at diagnosis did not correlate with tumor burden, as reflected by the white blood cell count (P Ͼ 0.05) or serum LDH (P Ͼ 0.05). In patients with B-NHL, there was no significant correlation between the LDH level and CSF-tau (P Ͼ 0.05).
Three patients with raised intracranial pressure (medulloblastoma), and one patient with a germinoma, from which CSF was taken for staging, had high CSF-tau concentrations (823, 1397, 1500 and 442 pg/ml, respectively), in contrast to one patient with grade I astrocytoma who had a normal CSFtau level (97 pg/ml). One patient with LCH had a normal CSFtau level of 112 pg/ml. Two patients with rhabdomyosarcoma could be analyzed at diagnosis: one patient with stage I disease had a CSF-tau level of 279 pg/ml, the other patient with stage IV disease had a level of 320 pg/ml. One patient with retinoblastoma and overt CNS involvement had a CSF-tau level of 1800 pg/ml.
Figure 2
CSF-tau levels at diagnosis of hematological malignancies. The CSF of patients with hematological malignancies was taken before any treatment was started. The CSF-tau levels are shown for each patient group.
Tau levels during treatment of non-B-ALL patients
The treatment for non-B-ALL consisted of a multi-drug induction phase, an interval phase consisting of high dose IV methotrexate (MTX) and four IT injections of MTX, a reinduction phase similar to the induction period, and finally a maintenance chemotherapy phase, according to the EORTC protocol 58881 (Table 2) . Mean CSF-tau values at each lumbar puncture are presented in Figure 3 . Significant increases in CSF-tau levels during the treatment course were observed when compared to levels at diagnosis (Kruskal-Wallis test: P = 0.01). Using the Dunn's multiple comparison test, significant increases were found at day 8 (P Ͻ 0.01), day 22 (P Ͻ 0.05) and day 52 (P Ͻ 0.01) during the induction, and at day 195 during the re-induction (P Ͻ 0.05) phase. When assessing the evolution of CSF-TAU compared to the individual values at day 1 using the Wilcoxon paired test, significance was reached at day 8 (P = 0.004), day 22 (P = 0.01), day 38 (P = 0.02), and day 195 (P = 0.01). When all values for each treatment phase were pooled together, significant increases were found between the CSF-tau values at diagnosis vs the median of the values obtained during the induction chemotherapy (Kruskal-Wallis test: P Ͻ 0.0001, Dunn's multiple comparison test: P Ͻ 0.001). In the multiple comparison test, no significant increase was found during interval, re-induction, and maintenance chemotherapy. It was suggested that children younger than 4 years are more vulnerable to the neurotoxic effects of chemotherapy. 13 We, however, did not find a stronger chemotherapy-induced increase of CSF-tau values in younger patients.
The highest tau values were seen during the induction period, in which 45% of analyzed samples (40/88) were higher than 500 pg/ml. This percentage then decreased to 17% (14/81) in the interval period, to 15% (3/20) during reinduc- tion, and finally to 12% (12/99) during the maintenance period. Three out of 28 patients followed in the longitudinal series already had values of tau Ͼ500 pg/ml before treatment, which normalized during induction chemotherapy (2/3) or interval therapy (1/3). CSF-tau levels above 500 pg/ml were observed during induction in 14 of the remaining 25 patients, in 4/25 patients during interval therapy, and in one patient during reinduction or maintenance chemotherapy. CSF-tau levels remained below 500 pg/ml during the entire course of treatment in only 11/28 patients. One particular patient was treated with prednisolone for 8 days without IT MTX at day 1, due to the high leukemic burden (610 000 WBC/mm 3 ). After 8 days of treatment, CSF-tau levels remained low, namely 155 pg/ml. Afterwards, this patient entered into the EORTC protocol as did all other non-B cell patients, receiving IT injections of MTX during the following weeks. Tau levels increased rapidly to 744, 948, 1120, 861, and 1023 pg/ml at days 12, 15, 18, 22, and 44, respectively.
One CSF sample was available from a child, treated in another center, who suffered from manifest neurotoxicity (diplegia) after treatment with MTX. The CSF-tau level in this Leukemia child exceeded the highest standard used (2000 pg/ml) for tau, reflecting gross neural dysintegrity.
Tau levels during treatment for B-NHL
Ten LPs are normally scheduled in the UKCCSSG 9602 protocol (Table 2 ). In our study, only six children could thereby be followed longitudinally. Therefore, statistical analyses were not performed. Data of pooled samples at each LP during the treatment course are presented in Figure 4 . Striking differences with respect to chemotherapy-induced increases of tau in the CSF were detected in the B-NHL children, treated according to the UKCCSG 9602 protocol (Table 2) , as compared to the children treated for non-B-ALL with the EORTC protocol. During induction chemotherapy, treatment with one IT MTX injection and 7 days oral corticosteroids, along with one i.v. administration of vincristine and cyclophosphamide resulted in an increase of CSF-tau by a factor of 7.77 (min 2.96, max 13.78) at day 8. Moreover, in 5/6 patients, at least one sample contained more than 500 pg/ml of CSF-Tau. Figure 5 shows the results of a single patient with B cell leukemia, who was CSF-tau levels during the course of chemotherapy for non-B-ALL. CSF was taken at each LP for the detection of tau. The data were derived from the 28 patients which could be studied longitudinally. Results are mean ± s.e.m.
Figure 4
CSF-tau levels during chemotherapy for B-NHL. CSF was taken at each LP for the detection of tau. Data are expressed as mean ± s.e.m. treated according to the high risk arm of the UKCCSG 9602 protocol. Also in this patient, an obvious increase of CSF-tau during chemotherapy was documented. Figure 6 shows the evolution of tau in individual patients with AML, treated according to the EORTC 58921 protocol. Patients 11 and 23 did not show a significant increase in tau during treatment. Patient 11 went into complete remission, while patient 23 died after relapse. Longitudinal data were available from one out of two patients with Down's syndrome, and this patient had tau levels slightly above 300 pg/ml. This patient is in complete remission. Patient 12, from whom LPs were taken at days 1 and 8, had an aggressive disease and died early after bone marrow transplantation. Patients 35 and 51 started with a CSF-tau level above 300 pg/ml at diagnosis. A further increase of CSF-tau was observed in patient 35, who was treated with chemotherapy. This patient died after relapse. Patients 69 and 89, with evidence of CNS invasion at diagnosis, both had a tremendous increase of tau in the CSF
Evolution of tau levels during treatment for AML
Figure 5
CSF-tau levels during chemotherapy of a single patient treated for B cell AL. CSF was taken at each LP for the detection of tau. during treatment, reaching values far above the pathological range which starts from 500 pg/ml. Patient 89 currently is on maintenance chemotherapy, and is currently in complete remission. Patient 69 had bone marrow relapse. LPs were performed on the occasion of new induction chemotherapy on days 243 and 250; the CSF-tau values were 379 and 397 pg/ml, respectively.
Discussion
In the present explorative study, two important results emerged. Firstly, in children with hematological malignancies, 16/50 children, which included the two children with CNS invasion, demonstrated elevated CSF-tau levels above Leukemia 300 pg/ml before any treatment was initiated. Secondly, during chemotherapy for non-B-ALL or B-NHL, a significant increase of CSF-Tau was found, already after the concomitant administration of only one IT MTX injection and systemic corticosteroids, while in patients treated for AML, CSF-tau was increased only in the two patients with CNS involvement. The increased CSF-tau levels reached pathological levels (considered arbitrarily as Ͼ500 pg/ml) observed in other neurodegenerative disorders. 5 At diagnosis, tau was not correlated with markers of disease activity in non-B-ALL such as the total amount of white blood cells and the serum LDH value. This finding reflects the brain as being excluded from the leukemic process in most of the children. However, CNS leukemia can be found at diagnosis in fewer than 5% of children with NB-ALL.
14 Diagnosis of meningeal leukemic invasion requires cytologic confirmation of leukemic cells in CSF. 15, 16 In symptomatic patients, CSF pressure is usually increased, and elevated CSF protein and hypoglycorrhachia are common. With meningeal leukemic invasion in the asymptomatic patient, CSF pressure may be normal, CSF leukemic cell counts relatively low, and abnormalities in CSF chemistry determinations absent. If there is no significant pleocytosis, the diagnosis of meningeal leukemia is more problematic. 17 The leukemia status in the CNS is now classified as CNS-1 (no lymphoblasts), CNS-2 (Ͻ5 WBC/l with definable blasts on cytocentrifuge examination), and CNS-3 (Ͼ5 WBC/l with blast cells or cranial nerve palsy). 18 In our study, two patients with proven meningeal involvement had tau levels at diagnosis which exceeded the upper normal limit. However, it was curious that some patients with no clinically apparent CNS disease (no malignant cells, normal CT scan, normal fundoscopy) had elevated CSF-tau levels. A possible explanation is that the elevated tau values in these patients before the initiation of any treatment is correlated with tumor activity within the parenchyma of the brain, which was not detectable with standard diagnostic procedures, and which normalized after treatment. Although anatomic evidence supports the concept that leukemic cells infiltrate by way of perivenous adventitial tissue connecting the dura mater and subarachnoid space, 19 direct hematogenous spread of mitotically competent leukemic cells to brain parenchyma has been suggested as well. 20 The elevated CSF-tau levels that accompanied the diagnosis of children with medulloblastoma or germinoma and raised intracranial pressure, and of one child with retinoblastoma with CNS invasion, but not of children with astrocytoma grade 1 or with rhabdomyosarcoma further support CSF-tau as a marker of disease-related neural dysintegrity. Prospective trials should be set up to investigate whether the elevation of CSF-tau concomitant with the diagnosis of hematological malignancies reflects a new risk group of CNS disease, and whether the measurement of CSF-tau can contribute to the primary diagnosis and staging of the leukemic process.
During the induction period in non-B-ALL patients, when prednisolone and IT MTX was scheduled in the treatment protocol at day 1, a significant increase in CSF-tau was already observed at day 8. By contrast, in the single patient treated with prednisolone alone for 8 days without any IT MTX, the CSF-tau value was still normal at the time of the first LP. Moreover, the re-induction treatment for non-B-ALL including dexamethasone for 21 days resulted in only a slight increase of CSF-tau. On the other hand, during the interval therapy for non-B-ALL, four courses of i.v. high-dose MTX and IT MTX did not result in increased CSF-tau levels. It should, however, be noted that at that time point, folinic acid is added together with the high-dose MTX infusion for detoxification. Therefore, a protective effect of folinic acid against MTX-induced neural damage can not be excluded. Finally, we observed a patient treated for metastatic medulloblastoma with systemic cyclophosphamide, vincristine, MTX, carboplatin, etoposide and intraventricular MTX prior to radiotherapy, and found a sharp decline in the tumor-induced high CSF-tau level, in spite of 24 intraventricular MTX injections (data not shown). This patient, however, did not receive corticosteroids. Neurotoxic sideeffects of both glucocorticosteroids and MTX are widely known. [21] [22] [23] [24] [25] [26] [27] [28] [29] It appears that the combination of both systemic prednisolone and IT MTX was associated with elevated CSFtau. The hypothesis that neurotoxic effects are induced by the combination of prednisolone and MTX accords with data demonstrated in an animal model, in which it was shown that prednisolone altered behavioral outcome by enhancing the biological (toxic) effects of MTX. 30 On the other hand, MTX alone without corticosteroids is well known to cause CNS toxicity, and this is exemplified in the patient with diplegia after MTX, showing extremely high CSF-tau levels.
In the patients with non-B-ALL, high CSF-tau levels were observed during the whole period of induction chemotherapy. After 8 days, however, vincristine is added to the therapy. Vincristine induces neuropathy of peripheral and cranial nerves by blocking axonal transport in the axonal microtubules. 31 Moreover, asparaginase is added from day 12 until day 35, and is known to be neurotoxic after several weeks of therapy, based on coagulopathies, causing either intracerebral hemorrhage or thrombosis and cerebral infarction. 31 It cannot be excluded that asparaginase-induced coagulopathies in the brain microcirculation can cause neural damage and, as a consequence, an increase in CSF-tau levels, without overt symptoms.
The increases of CSF-tau in patients treated for B-NHL were higher than in patients treated for non-B-ALL. However, these patients not only received the combination of systemic prednisolone + IT MTX, but also vincristine and cyclophophamide, as well as IT hydrocortisone. We hypothesize that the vincristine and/or the IT hydrocortisone further strengthen the effects on CSF-tau of systemic prednisolone + IT MTX. In the treatment schedule for B-NHL, the COP protocol is immediately followed by COPADM 1. Nevertheless, after the initial release of CSF-tau, no further or prolonged tau increase was found in these patients, and tau declined to the levels before diagnosis in approximately 1 month. However, from the time of COPADM 1, folinic acid is added to detoxify high-dose i.v.
MTX.
An increase of CSF-tau during treatment was not observed in the patients treated for AML, except in the two patients with proven CNS invasion. In this treatment protocol, i.v. and IT Ara-C is given. Neurotoxic effects of Ara-C include dysarthria, dysdiadokinesia, ataxia, and to a lesser extent, somnolence, confusion, disorientation, memory loss, cognitive dysfunction, headache, and seizure activity. The mechanisms might involve cerebellar degeneration that would occur as a result of the Ara-C metabolites in the CSF. During an infusion, the concentration of Ara-C in the CSF reaches 40-60% of the plasma concentration and may accumulate in the CSF for 48 h. 32 It is not clear why no increase in CSF-tau was observed in patients without CNS involvement. However, only a limited number of patients has been studied thus far. Moreover, LPs are not frequently scheduled during the treatment course, and no LP is scheduled at the time of the highest i.v. dose of Ara-C (Intensification 1). Finally, we cannot exclude that the patients with CNS involvement are more vulnerable to neurotoxic effects of chemotherapy due to alterations in the blood-brain barrier, exposure to higher Ara-C concentrations, and biological (toxic) effects in the parenchyma of the brains. 33, 34 In the patient group treated for hematological malignancy described in this paper, no obvious clinical neurotoxicity was observed, except in the single patient with the diplegia induced by MTX, who had an extremely high tau level in the CSF reflecting major neurotoxicity. In spite of the known severe toxicities related to MTX, 28, 29 one should take into account the insidious chemotherapy-related neurotoxicity. Recent reports suggest that children under chemotherapy, without radiotherapy, suffer from specific neuropsychologic dysfunctions. 29, 35 Measuring tau levels in the CSF during treatment might reflect ongoing chemotherapy-related neurotoxicity, caused during induction chemotherapy, which is mostly subclinical at the time of diagnosis, but detectable by specialized investigations in the long-term follow-up. CSF-tau, which is used in the present study, has already been validated in several neurodegenerative disorders. 5, 6 However, the relevance of a transient increase in CSF-tau to the biology of treatmentrelated neural dysfunction is not known. We are now investigating a putative correlation between the transient increases of CSF-tau during the first phase of treatment with impairments found in neuropsychologic tests after treatment.
Several additional markers can serve as indicators of neuronal or glial damage, such as neuron-specific enolase (NSE), S100, myelin basic protein (MBP) 2, neurofilament, and glial fibrillary acidic protein (GFAP). 36 However, the exploratory nature of this study and availability of CSF-tau as a marker for neurodegeneration [5] [6] [7] led us to use this test as a first indication for neuronal damage. Upon carrying out NSE determinations in a large subset of these CSF samples, results emerged that were similar to those observed with CSF-tau (unpublished observations).
In conclusion, this study demonstrates that some patients have elevated tau levels in the CSF at the time of diagnosis which might indicate CNS invasion, and that chemotherapy is associated with tau release in the CSF, which may reflect chemotherapy-induced neural damage.
